{"id":90846,"date":"2026-11-12T16:00:00","date_gmt":"2026-11-12T16:00:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=90846"},"modified":"2026-11-13T02:13:02","modified_gmt":"2026-11-13T02:13:02","slug":"antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/","title":{"rendered":"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline"},"content":{"rendered":"<p><em>North America Holds 50% of a USD 14.09 Billion Market, HER2 and Breast Cancer Lead, and Trop-2 Grows Fastest: Precedence Research Segment, Company and Buyer Intelligence<\/em><\/p>\n<p>Ottawa, Nov.  12, 2026  (GLOBE NEWSWIRE) &#8212; <i>The global antibody drug conjugates (ADC) market is valued at USD 14.09 billion in 2026, up from USD 12.69 billion in 2025, and is projected to reach about USD 34.80 billion by 2035 at a CAGR of 10.61%. North America held 50% of 2025 revenue, and the U.S. market is set to grow from USD 4.45 billion in 2025 to about USD 12.29 billion by 2035.<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"329.99px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/6ca99ede-f462-4771-88ce-7de949a8e3d3\/image1.png\" width=\"586.65px\" data-dpi=\"72\" data-filename=\"image1.png\" \/><\/p>\n<p>Precedence Research today released updated intelligence on the global <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FtaZGYRALTcq1av6ErsK3naDLqUIzD97PnfTTqIzspZS4XobUTKqZv1oZedPTBR9_s1c60drpp1J0cn9laXdM1zI_h9v-f2vTVQLvsL89CUQzZ2Lrj_7opHIszsgA0NIQkppQNdFc1uy_DEEWBygqLcu2bqZ1PD8_OeLMGZAQdA=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>antibody drug conjugates market<\/b><\/a>, covering targeted cancer medicines that link a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KwDeQ3xbKWxOLxojDXbLE7HSF896XzN36LZuH5EnMGvLXPKtMP9fsTki4HauHA1AGOcLp0YXfmwTxjAyi363jvGbJ-I78agHESARr9QfCL_a5HKQFsHusaXF06dkYqIl0e1AFVBDuls9BOBTBVTNGD3kmalr1QdlDklEvYpTRqI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>monoclonal antibody<\/b><\/a> to a potent cytotoxic payload, so the drug is delivered mainly to tumor cells.<\/p>\n<p>ADCs are moving from late-line to earlier treatment. In May 2026 alone, the U.S. Food and Drug Administration approved Enhertu for two early-stage HER2-positive breast cancer settings, approved Datroway as a first-line therapy for metastatic triple-negative breast cancer, and approved AbbVie&#8217;s Decnupaz, the first ADC for a rare blood cancer called BPDCN. Earlier use means more patients treated for longer, which supports steady growth across the forecast period.<\/p>\n<p>The pipeline is also changing hands. Chinese developers are now a major source of new ADCs, and global drugmakers are licensing them at scale: Pfizer agreed a collaboration with Innovent worth up to USD 10.5 billion in June 2026, and Roche partnered with Hansoh in October 2026 in a deal that could exceed USD 15 billion. For drug developers, CDMOs, hospitals, payers and investors, the questions are which targets and payloads will win, who controls manufacturing capacity, and how fast new ADCs reach earlier lines of therapy.<\/p>\n<p><b>Full report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pf6Bn5vDWnVHjpIaw-EpUQfzJwpJtNFKjKX6pbYTRI8x4cRL4EX9cJos33xAIbrxOKfVqMW56RsjO4-1fgiQz4Xq6tVAUqulGvi3-4gs8_lKNDD4gbh-mdy9UrQhvoL9CRQYf1Fkid65jCd3HI1uqijIu-lNielo6R_AfxX0EVfb8TQo2usXLKX3jdXuJ8szuZh8OGUhob6seuIfVseABQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-drug-conjugates-market<\/a><\/p>\n<p><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pf6Bn5vDWnVHjpIaw-EpUQfzJwpJtNFKjKX6pbYTRI97l3C5t-nK-PqLJHJoc68froPAox6l5S9Nt9ZaStRvTXHGbmwDG8vszJG9JUgqqw1HT-ZwPGn8MZBaH0ETs_Z1bFwrj5ooeXbPy9BovY7kcLqwPnuyGEOziLDcLmgo_VA=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/2645<\/a><\/p>\n<p><b>Market Size and Growth<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Market Indicator<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Value<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Global market size, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 12.69 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Global market size, 2026<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 14.09 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Forecast market size, 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">About USD 34.80 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAGR, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">10.61%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Absolute growth, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 20.71 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. market size, 2025 \u2192 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 4.45 billion \u2192 about USD 12.29 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest region, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">North America (50%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing region<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Asia Pacific (around 19% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading antigen target \/ application, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">HER2 (24.40%) \/ breast cancer (28.90%)<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/8d682608-5ecf-453e-8fbe-f7599aac4e71\/image2.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image2.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 1: Antibody Drug Conjugates Market Snapshot<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>Growth rests on three factors: new approvals in earlier lines of therapy, expansion into tumor types beyond breast and blood cancers, and new targets such as Trop-2, which is the fastest-growing antigen target in the report.<\/p>\n<p><b>Segment Intelligence: Dominant and Fastest-Growing Segments<\/b><\/p>\n<p>The table below shows the leading segment in each group with its published 2025 share and a modeled 2026 value (USD 14.09 billion \u00d7 share \u00f7 100), alongside the fastest-growing segment.<\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/e607345b-075b-426d-8cbc-0b55b80dffeb\/image3.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image3.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 2: ADC Market Leading Segment Shares, 2025<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>ADC Market: Leading and Fastest-Growing Segments<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Segment Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Leading Segment (2025 Share)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>2026 Value (modeled)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Fastest-Growing Segment<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Product<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Kadcyla (22.60%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 3.18 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Enhertu<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Antigen target<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">HER2 receptor (24.40%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 3.44 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Trop-2 (14.80% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Application<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Breast cancer (28.90%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 4.07 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Ovarian cancer (13.20% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">End user<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hospitals &amp; clinics (36.50%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 5.14 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Specialty cancer centers (12.40% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Distribution channel<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Direct sales (48.20%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 6.79 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Online platforms (11.60% CAGR)<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Product and target.<\/b> HER2-directed ADCs lead the market, with Kadcyla holding the largest product share in 2025. Enhertu is the fastest-growing product as its approvals move into early breast cancer and other HER2-expressing tumors. Trop-2 is the fastest-growing target, supported by Datroway and Trodelvy and by several Trop-2 ADCs from Chinese developers.<\/p>\n<p><b>Application.<\/b> Breast cancer leads with 28.90% of 2025 revenue. Ovarian cancer grows fastest, driven by folate receptor alpha-targeted ADCs such as AbbVie&#8217;s Elahere. Lung, urothelial, gastric and blood cancers are other key areas.<\/p>\n<p><b>End user and channel.<\/b> Hospitals and clinics lead because ADCs are given by infusion and need monitoring. Specialty cancer centers grow fastest as complex ADC regimens concentrate in high-volume oncology centers. Direct sales dominate distribution.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Regional and Country Analysis<\/b><\/p>\n<p><b>ADC Market by Region<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Region<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Position<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key Facts<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Growth Signal<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest, 50% of 2025 revenue<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. USD 4.45B (2025) \u2192 about USD 12.29B (2035)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Early-line FDA approvals<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Europe<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Second-largest<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">EMA approvals follow U.S. with a lag<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Broader reimbursement over time<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia Pacific<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing, around 19% CAGR<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">China is a major ADC innovation hub<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Out-licensing and domestic launches<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Latin America and MEA<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Emerging<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Access limited by price<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gradual reimbursement<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>North America.<\/b> The U.S. leads because most new ADCs launch there first and are used across a broad range of cancers. The May 2026 approvals for Enhertu in early breast cancer and Datroway in first-line triple-negative breast cancer will expand the treated population further.<\/p>\n<p><b>Asia Pacific.<\/b> Asia Pacific is the fastest-growing region. China has become one of the world&#8217;s main sources of new ADC candidates, and companies such as Kelun-Biotech, Hansoh, Innovent, Hengrui, RemeGen and Duality Biologics are licensing assets to global drugmakers. Japan is home to Daiichi Sankyo, the developer behind Enhertu and Datroway.<\/p>\n<p><b>Europe.<\/b> Europe is the second-largest region, supported by EMA approvals and growing ADC manufacturing capacity. Axplora is expanding lyophilization capacity for ADCs at its Le Mans site in France, with completion expected in 2027.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>What Is Changing in the Industry<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/e7293eab-7ca2-49c3-9fa1-0d152d8b8dee\/image4.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image4.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 3: Key ADC Developments, November 2025 \u2013 October 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>ADCs are moving into early-stage and first-line treatment.<\/b> In May 2026, the FDA approved Enhertu for neoadjuvant use with THP in stage II\/III HER2-positive breast cancer (DESTINY-Breast11) and as adjuvant monotherapy, where it outperformed Kadcyla (DESTINY-Breast05). The FDA also approved Datroway as a first-line therapy for metastatic triple-negative breast cancer.<\/p>\n<p><b>What it indicates:<\/b> ADCs are replacing older standards of care. Treatment in earlier disease means more patients and longer therapy, which shifts share from Kadcyla toward Enhertu and other next-generation ADCs.<\/p>\n<p><b>New targets and blood cancers are opening.<\/b> On May 27, 2026, the FDA approved AbbVie&#8217;s Decnupaz (pivekimab sunirine), a CD123-directed ADC and the first ADC for adults with blastic plasmacytoid dendritic cell neoplasm.<\/p>\n<p><b>What it indicates:<\/b> ADC use is spreading beyond HER2 and Trop-2 into rare and hematologic cancers, adding new revenue streams.<\/p>\n<p><b>Global drugmakers are licensing China&#8217;s ADC pipeline.<\/b> Pfizer and Innovent agreed a global collaboration in June 2026 worth up to USD 10.5 billion, including USD 650 million upfront, focused on ADCs with novel payloads and multi-specific antibodies. In October 2026, Roche partnered with Hansoh in a deal that could exceed USD 15 billion.<\/p>\n<p><b>What it indicates:<\/b> China is now a primary source of ADC innovation, and licensing will remain the fastest route for large pharma to refill pipelines.<\/p>\n<p><b>The technology is evolving beyond cytotoxic payloads.<\/b> C4 Therapeutics and Roche announced a collaboration on degrader-antibody conjugates in April 2026. Startups are raising capital for new designs: Solve Therapeutics secured USD 120 million and NEOK Bio raised a USD 75 million Series A in November 2025.<\/p>\n<p><b>What it indicates:<\/b> Next-generation payloads, bispecific ADCs and degrader conjugates aim to widen the therapeutic window and reach tumors that resist current ADCs.<\/p>\n<p><b>Manufacturing capacity is expanding.<\/b> Axplora announced added ADC lyophilization capacity in February 2026, and CDMOs such as Lonza, WuXi XDC and Samsung Biologics continue to add high-potency conjugation capacity.<\/p>\n<p><b>What it indicates:<\/b> ADC production needs specialized containment and conjugation skills, so CDMO capacity will be a competitive factor for developers.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Rising cancer incidence and demand for targeted <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i-77ZEHel4uKjiiqecOqf5zhpnOYW8IgYYRiQcF_Htkl2OZQH6-dhwg_fp7Lh5wxSveozQy9pjIxQi7WeMNUFgfvOUERwq99pyPsmMd8zzYTI_eQxWoUpHkciARlKgkdGtLT57C-syUcw1unmXtRow==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>cancer therapeutics<\/b><\/a> with fewer side effects than chemotherapy.<\/li>\n<li style=\"margin-bottom:4pt;\">Regulatory approvals that move ADCs into earlier lines and new tumor types.<\/li>\n<li style=\"margin-bottom:4pt;\">Strong <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y-m7jpb8ii8CIB7bs3YlaT8J7X2w10k5A7B9BB48cZ_ejJsDznao07x1-whW3uxIyD8iwRMf0Nmt9dVmO474kbYyDScpBzCelrcZ2c8Gmx0zUPUlgkzaVc69J-0C9_148KthJzk5qKqqUsD5q-atdkjqqMpVm1K4NrsLxQTS4Odlqx6ct94wFtA87S187g1pnHceTaS6f0LtwbGU5ht0AA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>clinical trials pipelines in the U.S., Europe, Japan and China<\/b><\/a>.<\/li>\n<li style=\"margin-bottom:4pt;\">Large licensing deals that fund global development of new ADCs.<\/li>\n<li style=\"margin-bottom:4pt;\">Advances in linkers, payloads and site-specific conjugation that improve safety and stability.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Toxicities such as interstitial lung disease and ocular effects that require close monitoring.<\/li>\n<li style=\"margin-bottom:4pt;\">Complex, high-cost manufacturing with high-potency containment needs.<\/li>\n<li style=\"margin-bottom:4pt;\">High treatment prices and reimbursement limits in many countries.<\/li>\n<li style=\"margin-bottom:4pt;\">Resistance to existing payloads and crowded competition around HER2 and Trop-2.<\/li>\n<li style=\"margin-bottom:4pt;\">Patent and supply chain risks tied to cross-border licensing.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Trop-2 ADCs<\/b>, the fastest-growing antigen target, in breast, lung and other solid tumors.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Ovarian cancer<\/b>, the fastest-growing application.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Bispecific ADCs and degrader-antibody conjugates<\/b> as next-generation designs.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>ADC manufacturing services<\/b> for high-potency conjugation and fill-finish.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Specialty cancer centers<\/b>, the fastest-growing end user, as ADC regimens become more complex.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company and Competitive Intelligence<\/b><\/p>\n<p>The market is led by a small group of companies with approved ADCs: AstraZeneca and Daiichi Sankyo (Enhertu, Datroway), Roche (Kadcyla, Polivy), Pfizer (Adcetris, Padcev and Tivdak through its Seagen acquisition), Gilead Sciences (Trodelvy), AbbVie (Elahere, Decnupaz), Takeda (Adcetris outside the U.S.), GSK and ADC Therapeutics (Zynlonta). Chinese developers and specialist biotechs supply much of the next wave.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key ADCs \/ Assets<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Positioning<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Relevant Development<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AstraZeneca \/ Daiichi Sankyo<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Enhertu, Datroway<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leader in HER2 and Trop-2 ADCs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Two early breast cancer approvals and first-line TNBC approval (May 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Roche<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Kadcyla, Polivy<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest product share in 2025 (Kadcyla)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Degrader-conjugate deal with C4T (Apr 2026); Hansoh deal (Oct 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pfizer (Seagen)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Adcetris, Padcev, Tivdak<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Broadest ADC portfolio after Seagen<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Innovent deal up to USD 10.5B (Jun 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gilead Sciences<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Trodelvy<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Trop-2 ADC in breast cancer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Competes in fast-growing Trop-2 segment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AbbVie<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Elahere, Decnupaz<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Ovarian cancer and rare blood cancers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Decnupaz approved May 27, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Takeda<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Adcetris (ex-U.S.)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hematology focus<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Named key player in the report<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GSK<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADC pipeline<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Re-entering ADCs through licensing<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Named key player in the report<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADC Therapeutics<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Zynlonta<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Specialist in lymphoma<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Named key player in the report<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Large pharma business development<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Head of BD, Oncology R&amp;D Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pipeline gaps, patent expiries<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">In-licensing and co-development of ADCs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADC biotechs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CEO, CSO, CMC Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Funding rounds, IND filings<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CDMO capacity, linker and payload technology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hospitals and cancer centers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oncology Pharmacy Director, P&amp;T Committee<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">New approvals, formulary reviews<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Infusion capacity and toxicity management<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Payers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharmacy Director, HTA Lead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Early-line approvals, budget impact<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Value-based and outcomes contracts<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CDMOs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">BD Director, Operations Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pipeline progress, capacity gaps<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">High-potency conjugation and fill-finish<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>How Precedence Research Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset<\/b> provides segment, regional and company data for ADCs and adjacent markets such as the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rUDX7y-Z82uKG2FD1TUsKM5_QblsJTE_7kS8Q_pfwl2ctnWq9wHazLzub-TzsEDQvvCFIENRhj1OMINtn9vtd_DSp7Apv4qQUbzxxQF8DS641yTp1eFZnHBq4k-uAk73\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>oncology<\/b><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dMR6BcBpOAQ7cDAayizg4TcCZgwHlzzp_G6b2sd8KGRort96sZRd7AlDxe2YdniVTT2pzE-TBkB75tE-nGKDpuKCBJ0uDW39DkiGcZhILLfVPooV5DhNK4HhOlYHOje9q_klnuibNqN2gXSTTp363Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>bispecific antibodies<\/b><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FtaZGYRALTcq1av6ErsK3jRd9MGSfKJBUNqY27Q7yiyTj_vJecs9Srdwrj1AnxjngO45YeDFr853puCnM12ACTgowrOhiEc0HfDUbkyYv754SabFUWYueSgejF6qTvwxy0T4O-B70tD0fn7iJDDnNS5Z2u2gyZziiMOsOsZC75E=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>antibody production markets<\/b><\/a>. It helps teams size demand by target, application and region.<\/p>\n<p><b>Precedence Quadrant<\/b> compares ADC developers on approved products, pipeline depth, technology and partnerships, helping business development teams screen licensing targets.<\/p>\n<p><b>Interactive Intelligence Dashboard<\/b> tracks approvals, trial readouts, licensing deals and financings, so strategy teams can respond to competitor moves quickly.<\/p>\n<p><b>Quality &amp; Manufacturing Intelligence<\/b> maps CDMO conjugation capacity, high-potency suites and payload supply, supporting sourcing and partnering decisions.<\/p>\n<p><b>Customized Research<\/b> answers specific questions, such as Trop-2 competitive positioning, ADC opportunity in ovarian cancer or China licensing valuations.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Master Dataset<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Segment, region and company data on ADCs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sizes demand by target and indication<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Precedence Quadrant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Developer comparison on products, pipeline and deals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Screens licensing and partnering targets<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Interactive Dashboard<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Live tracking of approvals, trials and deals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Times BD and launch decisions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Quality &amp; Manufacturing Intelligence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CDMO capacity and payload supply mapping<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supports manufacturing partner choices<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Customized Research<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Target, indication and valuation studies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Answers decision-specific questions<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>ADC approvals, trial readouts and licensing deals arrive almost every month. Monthly updates suit business development teams tracking deals and data. Quarterly updates match drugmakers&#8217; earnings and product sales. Six-monthly updates help strategy teams follow major oncology congresses and label expansions, and annual updates support investors reviewing market size and share. Precedence Research offers all four update cycles.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>CEOs and CXOs:<\/b> the market adds USD 20.71 billion by 2035; early-line approvals make ADCs a core oncology franchise, not a niche.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Strategy and business development teams:<\/b> China is the deepest source of new ADCs; deals worth USD 10\u201315 billion show the price of access.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>R&amp;D leaders:<\/b> differentiate with new payloads, bispecific and degrader conjugates, and targets beyond HER2 and Trop-2.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Procurement and CMC teams:<\/b> reserve high-potency conjugation capacity early as demand rises.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Investors:<\/b> Trop-2 and ovarian cancer are the fastest-growing target and indication; platform biotechs remain acquisition candidates.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>CDMOs and suppliers:<\/b> capacity expansions such as Axplora&#8217;s show strong demand for ADC manufacturing services.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"446.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/cc10c3ae-1d52-4bf4-8109-957dd3de9d5e\/image5.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image5.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 4: Antibody Drug Conjugates Company Ecosystem, 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>To understand which ADC targets, companies and partnerships will lead through 2035, explore the full report or speak with a Precedence Research analyst.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltvZ0pgRlxIWVc33lB3YFkIsNsh8xY2BAssLqxGRjMb9_tU_4voroFszAIZ-P2DC1MjIPfeSrTbpg-cr7S6Xzmg3arzomjJP-oEBL51_gMh2FPNghMuN54w8hpMxBVJRshUH-z15l3q6Sfq7qQQmP7E3PUw4Ds6pmbaF-HhgHFaIw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-drug-conjugates-market<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUluXShYWtdwzqiP8KzyPhE4GU91tn2B5EEopUUeeV7yTj1TpfxJ74FcHLAjC0pdt09priFqJdKdXpYIpnaifgCMQCHfKYbJy3u7fzflAZG60UeZGSCOUbnMc6SH7onh-GEI=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/2645<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Schedule a meeting:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlusmshh_olu7gFOTN90qsV_1AUldDz7YbkF9l7nX3OghHPCQpYW8MEvfK_RIKPWmhI5NGfsZpwCkC6Hv5dr3TyYYXX9HpRJFhYuZhc6mUFKMbPsou4e_FfQthVOO13L2RA=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/schedule-meeting<\/a><\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples.<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=twXGzMtJrElCnI_gDVOQeP6fLfXZo2X3k5s6WEKZbYsD2TNqv2wFQbUE7N7G0A7p-J2VPALxp2D26wkpQMD_SmxWLB1JT8wzEnmJG6zKnAokUKShb5I9blVwhOJz5UmM\" rel=\"nofollow\" target=\"_blank\" title=\"sales@precedenceresearch.com\">sales@precedenceresearch.com<\/a><\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:3pt;\">Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu431fEmaiqIuHx99AQI2TOb1z9Ymrdvxstysy73YBdqgKHqYlN5_u6P_onpraOletjHimzYaQIwUtdQsEuD66mJ10zbJ0Ff3obgQUHxNnvx6FblZ0vprrn7uRzoMYmYcw=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Therapeutics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu7Pxtp9F_JEBW6wog-PbamGifF-E8mC-JspMfEtao8UBZliN6HvrR0BCAiO-cY4Jd6G1nFhFLbpJ8qyy44xd7wVnK0B0QL29GL1ey-tX-_0Ayk0O9R7aWyUaClOzCteUIJFtUso1NDOOfoaZDOIcKOI8Zld7rkLpPxjhgLrWj_hw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-therapeutics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu7Pxtp9F_JEBW6wog-PbamM6qrYGURCaNF50Q1wRUQ8QQ1tLdQlPoD5nMDO0GYq8YuppHdcfafW4Ev_AVWkzmmCXFAn9NkMUn_fzxioC1NDRD7gyyTjkPGtJWwTAI50ZioCP19gIumULlqKt_80aEj\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Monoclonal Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltxl5clDW0MiWAZ0yIDoIcEWHziNqQpZq8gA5vqhQ5DZsxlYTG5iqD571F5DzsoT51U0lteEyDW3S8uf_38o3jh1Moqt07BdyVT4-lyS7iFMQgFP8o2fnBZHbTbVJsk5Dh3J-1Ke_0OxXUgo1wwO98jJEtY-vwm843FaPVkXWaqDg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/monoclonal-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Monoclonal Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu7Pxtp9F_JEBW6wog-Pbam1W87Lhs1MF_kjdA9jlIU23Z5QRc_Howi-KqVH3vgq8CdGx0zvpe2RCYgmitGTpZdVqTwLHAv3wfVFsl6jQJWr-HAcd4HU5zeJNHgjUx5iufN7AYEGfMdsqpNeH-zm4Zxc7mwapPs887LgKWJLXkhfYsI0dNJHH6gtZeiG91gm5g=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-monoclonal-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Bispecific Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlsVC6M5brVucKuqCqDSZOj5WskTcxqQvKrFXYSVQElaf7hRAgjR-rersam_CcIuSzRUGql4qi-BvpwJ7kcArG2t_hjo7nT5PeMDPKVttJRuVnZ-1vB7tT1FthAH9C8XCYhd08N1DuzPtBWn-EEaeYou1E1S3GccPqUZwoslKdd8cw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/bispecific-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biosimilar Monoclonal Antibody Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlsVC6M5brVucKuqCqDSZOj5GoF9HuQxwHxg1cTs4pc3XrUjFl_RRK8TDRk0iOU7q2AsE8brc3IoJhDoB888pRo3SqH_m73mMFUPWMI6iM0N4iA7gCOwQzbUuYcMx5-H7RYDVgNtwpBLEgDKcDWaGzfYJG6LnaKIebiHokYAefB-WjbwPIX2eh7iBJMay_MYaIw=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biosimilar-monoclonal-antibody-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Antibody Production Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltvZ0pgRlxIWVc33lB3YFkIQkAZmc6zQiqBewpoK3wnt9dxLrDly_UEjoZzBICEbVNXxOv9JOAfwdY55ty2ZD9jZAPuUg-HqvdX6NI0izNdrF76-fQy5AsmSSMIrP-mLcIEhlSScKcmuPiIqlsxybZIAt_LbtfV95lvWWPdK0euUw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-production-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Antibody Discovery Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltvZ0pgRlxIWVc33lB3YFkI8tusjtGwpYaQoaXKPLwbBD2B8Kt5yur1AN-q54xTLFyUhplV41abS13JaSeNv123RzaSCI4gW3tbGvdTICvNTuoHl8vnBonTzjAF_WAQzywBRrs1TpjLcgg8rpTnoPOO\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-discovery-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Antibody Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltvZ0pgRlxIWVc33lB3YFkI_cA7o2LAWs1yTN4hnaRZGvG1WQn3ZoWWlvbgTl2nIdTPeGdZux4dKqpcer-tmMwRERx9o8QTeuCKqhfMTCyh4Is0uo8WGpVMzEvmQVz9eY_ABmNALDz5nWPODyAxScGd\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-therapy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Chemotherapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltrJmOFLuPSXtaw5cnDfnjTCrLtw6ZKZDdGN3L-7VDIH57aX5auOSXvgX8lSW5QT4AyOLQudK-7SeQCt8HsIoqSsJBhsSCuBQnuqXvcq28UWj09-i5H0A90P3QF0uMk31vuShK_BmRwnIz6b2ZKw-0_\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/chemotherapy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Precision Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlsJokbg6IewYLdnaZukxkFtT1fdn0kSq6ln0mWvX7yC7Z-lop2HrQ1cqan4LZdy9WkJp5qlkMI7ZGUjfXOYIyr_24hKjng6na4f4N2fC0QWp2cDCv7bKvjU4oiWD_TSirEtmuh9cyPFtgdcWZPK_-ic\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/precision-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Diagnostics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu7Pxtp9F_JEBW6wog-PbamZJJIMldERMIVUWpr5dHxgm0VbyXMiKXK093CvEK2alm3LMp5g0qfZOdLHIlMOgyiFSeLMGnlkPVt-d86e_2zPa7zBqEqYabKHT7ib-AKnXYdcjVp6_OCPO2L_SourwWZ\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-diagnostics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Oncology Molecular Diagnostic Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu431fEmaiqIuHx99AQI2TO-jQtlir5KBjmoFX_ftAIAt8F97PhkSaChKgSVujnhPXbAYrsefcGeQ6n1haSm8eQQfBvJsl69yu1P76vLE6HoK2kRxhoBQDxL0abd9z5A-TXhSGZT4yeRQ2_s8cCuQ2csnMxr88AQHn-15mvKbkiuSbOK7rlGWLS0HSop8_1dKQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-molecular-diagnostic-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Artificial Intelligence in Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltfc82A9ZlKsDVEEmWXHme7HPh5yBQHW9i6j17O_VXOHiQLgR8TlVqwKlL1C36Oe8h9KBlQSIcAu_bE5dx_kNg1rm0BlAwLqFi5YZbVpgxZfy_DvYxcjYySB49gtLAd2hwkeyKDJE7YTXZGtBxWbjFATukKKxToX3n33PYRIej-g-LgqFECgG7FxFRcKMRXEJGrLMsWuQUASz4dpWHOGgyg\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/artificial-intelligence-in-oncology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUltIteHQFkeSm1TtfS5KlX-p2OMoo4Gj-G0wUjhMSKIC2P4qLlh1xMoHmMs7IjabeMUZmWeKtl0tKcZ322X9X7oxlqolu4r2ZwSIhg1lqrGDsv1VXhA3fDVhxYMTSDxAZ8GEuKsaU7wvMGn87NWms2Wv\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biopharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlsVC6M5brVucKuqCqDSZOj5tucV3xGqeDlJknk4fmMQncgsHnLpPAy_EuSlSyEY53fF9ZJWe-_LASaOdaYSmBo6x6JpzHIowSLE-MsbckeLCjd-rEU0jpSn6tsKPNiL_uXbt0t7QP3UlzMl8h6jnhqr\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biopharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlusfVOwjrebTDYVt2jBWCGc1USRA_WJANHcJov2pY4wvGD8Mbv86Q9DdXOns3JDm20hms4BhBNlwGYh1TWvflRtJfF8G8rGgnax5VWK3ZQdMJsyzg-xvE-nwMgKo3DnciO-um5DAlT1kqSEK3ebrlI3\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biotechnology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlsVC6M5brVucKuqCqDSZOj5_smbVxSDsyiDkbclPCsXj45kxOyM0zW6uM6E3cR2ywZlJfZtN7J3wwQaEP7ed8INIVGVamnAc5kPRnjimg3xO_1baLLp1QmRh2Hzoud31XOeIj68F5dNmSK4Nl7rffRD\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biotechnology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Deep Learning Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDMV1dIytkBl2PNg20c9GUlu2LBTurDfYk_r5BuAXPgxAGfwYQ1JxgJ2OBtAzpPSVe5zlYI1E5jC4Ifg3xEx1qotje07Nsg1YHpgk2RniksgRxZ_UYcr8K-KXuC1QUF4XbaXz-3-lH0XlrzPKfV3F5r0IkOeZ7pPIpANhpMdGvxkl\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/deep-learning-market<\/a><\/li>\n<\/ol>\n<p><b>About Precedence Research<\/b><\/p>\n<p>Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, biotechnology, ICT, energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.<\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Towards Healthcare: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDGXSZoZUZDjab_nvVOkBnvLA8bDmk2kM7K9lvhxzL7WnMnrayy9CFEq2SvFRtzilBWZJA3enLOKZ0rzJvYIcvIF11XMR1BHP60KZuLyS0ab9\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardshealthcare.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Packaging: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDKe8JPtV-RSxW2D0gjWQW-HbcY9asXf-Pmi0wXt_MfCdnEr_kTGn0izn3zVUkGqlVWME7swXpKedMx1-hNuP-c9lLk4k3q5A5ZrZo9BcVM6T\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardspackaging.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Chemical &amp; Materials: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDImXNIQq6ZvJr9zQ3-xvYzGsUR6D2N7QkZ4072ucCiU4xmJahzcbVQ-jf5r--VWmuz2iNhKlP3f7JiEwuIPGlNxSb3hhV1C2dvaiWTXu_R5I3TaY9H3VI78nRtyRP5mOmA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardschemandmaterials.com\/<\/a><\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">USA: +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4pt;\">APAC: +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4pt;\">Singapore: +65 3105 1271<\/li>\n<li style=\"margin-bottom:4pt;\">Europe: +44 7383 092 044<\/li>\n<li style=\"margin-bottom:4pt;\">Email: <a href=\"mailto:sales@precedenceresearch.com\" rel=\"nofollow\" target=\"_blank\" title=\"sales@precedenceresearch.com\">sales@precedenceresearch.com<\/a><\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDNE3fv_Wpf1MDzPU0GTxThMDYo-aslD9MuqJZ0WpgZrtW1VYKO4hgzC1mzOaN_GbxGtW2fdIJ0ZzU28UbnEXdCzOdGvIbFsSeBwOedfjIOEEcILmHn8JOX9J8tstdNPRAhQjZ6CIOc0H_F-mJk-fLp4=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.linkedin.com\/company\/precedence-research<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Facebook: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDPNrB6eq6dc50QtIoNQxSpC3pDnnw167MXnaQaQRyUNK9qIE6q-HUFnRWUMJRps5ympaYDAluxFV79NF417DuGCyGlyz6HeA5fFby1_4ZU17OcBDOcsJowncVkdXCfo-tA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.facebook.com\/precedenceresearch<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">X: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDAw8w23GNrKzYdwMb01QsnVolRd5ei7RiLfmdiXQ_zCc6LIAkVNTQ-qfio7qMC-Tv_IBuRfsDfvTCUJpENw6Bvk=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/x.com\/precedence_r<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Medium: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5AmUfq6GkmJ4Cd6StpUiDE81JKdUy77_6HPM8flYwtr1Vo4TEN-spH3DkzgakwLsrfr_k1MjwntXummktTAjIGGJIC6ng32tnsPM8a39FtX7zkiG8U-s-eDtHxZ2VZOMivQmtSrTF6LWvWaHh6V4rw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/precedence-research.medium.com\/<\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/YjUzNGFhMzEtODE1Ni00YjI0LWE0YmMtODk4Y2NjMjc5ZTNjLTEyMTM4NDktMjAyNi0xMS0xMi1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>North America Holds 50% of a USD 14.09 Billion Market, HER2 and Breast Cancer Lead, and Trop-2 Grows Fastest: Precedence Research Segment, Company and Buyer Intelligence Ottawa, Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; The global antibody drug conjugates (ADC) market is valued at USD 14.09 billion in 2026, up from USD 12.69 billion in 2025, [&#8230;]\n","protected":false},"author":1,"featured_media":90847,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-90846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline\" \/>\n<meta property=\"og:description\" content=\"North America Holds 50% of a USD 14.09 Billion Market, HER2 and Breast Cancer Lead, and Trop-2 Grows Fastest: Precedence Research Segment, Company and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T16:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-13T02:13:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline.png\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline\",\"datePublished\":\"2026-11-12T16:00:00+00:00\",\"dateModified\":\"2026-11-13T02:13:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\"},\"wordCount\":2517,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\",\"name\":\"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-12T16:00:00+00:00\",\"dateModified\":\"2026-11-13T02:13:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline","og_description":"North America Holds 50% of a USD 14.09 Billion Market, HER2 and Breast Cancer Lead, and Trop-2 Grows Fastest: Precedence Research Segment, Company and","og_url":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-12T16:00:00+00:00","article_modified_time":"2026-11-13T02:13:02+00:00","og_image":[{"width":960,"height":540,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline","datePublished":"2026-11-12T16:00:00+00:00","dateModified":"2026-11-13T02:13:02+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/"},"wordCount":2517,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/","url":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/","name":"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-12T16:00:00+00:00","dateModified":"2026-11-13T02:13:02+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/antibody-drug-conjugates-market-to-reach-usd-34-80-billion-by-2035-as-early-line-approvals-next-generation-payloads-and-multi-billion-dollar-china-deals-expand-the-adc-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Antibody Drug Conjugates Market to Reach USD 34.80 Billion by 2035 as Early-Line Approvals, Next-Generation Payloads and Multi-Billion-Dollar China Deals Expand the ADC Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=90846"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90846\/revisions"}],"predecessor-version":[{"id":90848,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90846\/revisions\/90848"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/90847"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=90846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=90846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=90846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}